ClinicalTrials.gg
Active, not recruitingNCT06180889Updated Sep 17, 2025

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A Phase 2 interventional study of Enoxaparin and KN060 Low in Knee Arthroplasty, Total, sponsored by Suzhou Alphamab Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Suzhou Alphamab Co., Ltd. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

02

Conditions studied

  • Knee Arthroplasty, Total
03

In context

Lead sponsor

Suzhou Alphamab Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 75 years old (including the cut-off value);
  2. undergoing unilateral Total Knee Arthroplasty (TKA);
  3. Voluntarily participate in the study and sign a written ;

Exclusion criteria

Exclusion Criteria:

  1. There is a high risk of bleeding or abnormal bleeding related indicators:
  2. Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease.
  3. Acute myocardial infarction or ischemic stroke occurred within 6 months before screening.
  4. Presence of malignant tumors or history of malignant tumors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Active comparator
    Enoxaparin

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.

    Drug: Enoxaparin

  • Experimental
    KN060 Low (post-surgery)

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.

    Drug: KN060 Low

  • Experimental
    KN060 Middle (post-surgery)

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.

    Drug: KN060 Middle

  • Experimental
    KN060 Hight (post-surgery)

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.

    Drug: KN060 Hight

Interventions

  • 40 mg enoxaparin administered as subcutaneous injection once daily

  • Single dose of KN060 administered as intravenous infusion

  • Single dose of KN060 administered as intravenous infusion

  • Single dose of KN060 administered as intravenous infusion

06

What researchers measure

Primary outcomes

  1. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded

    DVT - Deep vein thrombosis / PE - Pulmonary embolism. All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 days

Secondary outcomes

  1. Incidence of composite endpoint of major and clinically relevant non-major bleeding

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 days

  2. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excluded

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 35\100 days

  3. Incidence of symptomatic DVT, non-fatal PE

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  4. Incidence of fatal PE

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  5. Incidence of unexplained death for which PE cannot be excluded

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  6. Incidence of composite endpoint of major and clinically relevant non-major bleeding

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 35\100 days

  7. Incidence of bleeding

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  8. Incidence of major bleeding

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  9. Incidence of clinically relevant non-major bleeding

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  10. Incidence of treatment emergent adverse event/adverse drug reaction

    All suspected events were reviewed and classified by the investigator

    Time frame: Up to 14 \35\100 days

  11. Plasma Concentration of KN060

    Time frame: Up to 100 days

  12. Pharmacodynamics index: Changes of plasma concentration of Free FⅪ from baseline;

    Free FⅪ: Free Factor XI; Factor XI is a clotting factor.

    Time frame: Up to 100 days

  13. Pharmacodynamics index: Changes of FⅪ activity from baseline;

    FⅪ: Factor XI; Factor XI is a clotting factor.

    Time frame: Up to 100 days

  14. Pharmacodynamics index: Changes of APTT from baseline;

    APTT: activated partial thromboplastin time;

    Time frame: Up to 100 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2023
First posted
Dec 26, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Dec 15, 2025
CompletionEst.
Apr 15, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06180889
Lead sponsor
Suzhou Alphamab Co., Ltd.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Dec 20, 2023
Primary completion
Dec 15, 2025 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Xianlong Zhang, Doctor
principal investigator · Shanghai 6th People's Hospital
Feng Yin, Doctor
principal investigator · Shanghai East Hospital of Tongji University
Zhenjun Yao, Doctor
principal investigator · Fudan University
Shijun Gao, Doctor
principal investigator · Hebei Medical University Third Hospital
Jun Lu, Doctor
principal investigator · Zhongda Hospital
Xinshe Zhou, Doctor
principal investigator · The First Affiliated Hospital Of Bengbu Medicai College
Rende Ning, Doctor
principal investigator · Hefei First People's Hospital
Lidong Wu, Doctor
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University
Wenming Zhang, Doctor
principal investigator · First Affiliated Hospital of Fujian Medical University
Yayi Xia, Doctor
principal investigator · Lanzhou University Second Hospital
Song Chen, Doctor
principal investigator · The Third Hospital of Changsha
Tan Lu, Doctor
principal investigator · The First Affiliated Hospital Of Xingxiang Medical University
Chunming Huang, Doctor
principal investigator · The People's Hospital of Gaozhou
Jun Xiao, Doctor
principal investigator · Tongji Hospital
Pengde Kang, Doctor
principal investigator · West China Hospital
Min Dai, Doctor
principal investigator · The First Affiliated Hospital of Nanchang University
Wei Huang, Doctor
principal investigator · First Affiliated Hospital of Chongqing Medical University
Jiangwei Li, Doctor
principal investigator · The Affiliated Hospital Of Guizhou Medical University
Bensen Tang, Doctor
principal investigator · Beijing Jishuitan Hosptial Guizhou Hospital
Li Sun, Doctor
principal investigator · Guizhou Provincial Peoples Hospital
Xu Cai, Doctor
principal investigator · Beijing Tsinghua Changgeng Hospital
Xin Wang, Doctor
principal investigator · Yantai Yuhuangding Hospital
Huiwu Li, Doctor
principal investigator · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KN060

Start the discussion